Ballicules.com

Benralizumab

FASENRA

What it isIL-5 receptor monoclonal antibody that depletes eosinophils; severe eosinophilic asthma and EGPA.

Why this oneIt causes near-complete depletion by antibody-dependent cytotoxicity rather than neutralizing IL-5; for asthma, every-eight-week maintenance dosing.

What limits itBenefit tracks eosinophil count. Hypersensitivity can end treatment; treat helminths first and never use it for acute bronchospasm.

FDA label

FDA dosingPopulationStartTargetMax
Severe eosinophilic asthma (add-on maintenance)Adults & pediatric ≥12 yr30 mg SC q4wk ×3 dosesthen 30 mg SC q8wk
Severe eosinophilic asthma (add-on maintenance)Pediatric 6–11 yr, <35 kg10 mg SC q4wk ×3 dosesthen 10 mg SC q8wk
Severe eosinophilic asthma (add-on maintenance)Pediatric 6–11 yr, ≥35 kg30 mg SC q4wk ×3 dosesthen 30 mg SC q8wk
Eosinophilic granulomatosis with polyangiitis (EGPA)Adults30 mg SC q4wk
Hypereosinophilic syndrome (HES)Adults & pediatric ≥12 yr30 mg SC q4wk

Renal Undefined

Hepatic Undefined

Instructions

Cautions

Adverse reactions

Pregnancy Insufficient data; monoclonal antibody crosses placenta (3rd trimester).

Lactation No human milk data; IgG present in human milk in small amounts.

NO BOXED WARNINGS

Classes and tags

Clinical profile

Direct muscarinic antagonism0 / 4

Mechanism of action: Benralizumab ballicule

Benralizumab ballicule: receptor binding, kinetics and half-life diagram

Open Benralizumab in the interactive console ↗

Memory aids: mascots and interaction avatars

Benralizumab FASENRA mascot mnemonic cartoon
“Fasten in Bent rail”

Open Benralizumab in the interactive console ↗